Using Evidence to Improve Population Health

An endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience

What’s New

Milbank Blogs

  • How Well Does State Supervision of Hospital Mergers Work?

    Jul 8, 2019 | Erin C. Fuse Brown

    In a new Milbank blog post, Erin C. Fuse Brown, associate professor of law at Georgia State University College of Law, reports that the research presented at the workshop gave a mixed picture of COPA’s impact on price and quality. The experiences of states highlighted the importance and difficulty of sustaining COPA supervision over the long-term. Nevertheless, COPAs may be an appropriate policy tool in some circumstances, such in rural or semi-rural areas with little competition. Read more

States Tackling Health Care System Transformation with Federal Support

In the first of a new Milbank Memorial Fund series, Research Into Practice, Jennifer Lloyd et al. discuss three Milbank Quarterly articles that address whether state government is an effective agent for transforming health care systems within the United States. The brief is the first in a series that aims to make the research findings from Milbank Quarterly studies and their policy implications more accessible to policymakers and practitioners.

Read more

  • Early View


    Patent Eligibility Reform and the Public Health

    July 2019 | Jacob S. Sherkow

    The 2013 U.S. Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. was seen by many as a triumph for public health. The opinion found human genes were ineligible for patent protection, allowing many companies to offer single-gene diagnostic tests, like those for breast and ovarian cancer risk, which were at issue in Myriad Genetics. Read more

  • Early View

    Original Scholarship

    Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015

    July 2019 | Audrey D. Zhang, Jason L. Schwartz, Joseph S. Ross

    Conventional wisdom suggests that Food and Drug Administration (FDA) actions always reflect FDA advisory committee recommendations. But the FDA disagreed with 22% of its advisory committee recommendations over an 8-year period. Read more

View the current issue of the Quarterly

Latest Reports, Issue Briefs, and Case Studies

See all Publications